A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials

References

• Dawson J, Linsell L, Zondervan K, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology 2004;43:497-504
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317-20
   PubMed Web of Science ®Google Scholar
• Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63:901-7
   PubMed Web of Science ®Google Scholar
• IMS Health Inc. IMS National Prescription Audit, 2007 12 months preceding July, 2008
   Google Scholar
• Humphreys A, Mayer R. MedAdNews 200 – World's Best-Selling Medicines, MedAdNews, July 2007
   Google Scholar
• Sweetman SC (ed). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Available at: http://www.medicinescomplete.com/[Last accessed 5 November 2010]
   Google Scholar
• Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin 2010;26:1715-31
   PubMed Web of Science ®Google Scholar
• Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002;26:139-42
   PubMed Web of Science ®Google Scholar
• Mastbergen SC, Jansen NW, Bijlsma JW, et al. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 2006;8:R2
   PubMed Web of Science ®Google Scholar
• Blot L, Marcelis A, Devogelaer JP, et al. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000;131:1413-21
   PubMed Web of Science ®Google Scholar
• Dingle JT. The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage 1999;7:313-14
   PubMed Web of Science ®Google Scholar
• Henroitin Y, Reginster JY. In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage 1999;7:355-57
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Rachita C, Aisen PS, et al. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 2001;19:S7-S11
   PubMed Web of Science ®Google Scholar
• Ding C, Cicuttini F, Jones G. Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am J Med 2009;122:836-42
   PubMed Web of Science ®Google Scholar
• Reijman M, Bierma-Zeinstra SM, Pols HA, et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 2005;52:3137-42
   PubMed Web of Science ®Google Scholar
• Brizuela NY, Montrull HL, Demurtas SL, et al. Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers. Rev Fac Cien Med Univ Nac Cordoba 2007;64:9-15
   PubMedGoogle Scholar
• Yang SF, Hsieh YS, Lue KH, et al. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Clin Biochem 2008;41:109-16
   PubMed Web of Science ®Google Scholar
• Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal antiinflammatory drugs. Clin Med Res 2007;5:19-34
   PubMedGoogle Scholar
• Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared to traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand 2004;48:525-46
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-28
   PubMed Web of Science ®Google Scholar
• Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs? Can Fam Physician 2001;47:1398-400
   PubMedGoogle Scholar
• Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;25(1):CD004257
   Google Scholar
• Watson MC, Brookes ST, Kirwan JR, et al. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000;(2):CD000142. Review. Update in: Cochrane Database Syst Rev 2007;(1):CD000142
   PubMedGoogle Scholar
• Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 2002;41:1052-61
   PubMed Web of Science ®Google Scholar
• Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial. BMC Musculoskelet Disord 2005;6:58
   PubMed Web of Science ®Google Scholar
• Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003;19:725-36
   PubMed Web of Science ®Google Scholar
• Ghosh S, Paul S, Das N, et al. A study on the effects of diclofenac sodium and etoricoxib in the treatment of osteoarthritis. J Indian Med Assoc 2007;105:260-62
   PubMedGoogle Scholar
• Voltaren Official FDA Information. Revised: 03/2009 Novartis Pharmaceuticals Corporation. Available at: http://www.drugs.com/pro/voltaren.html [Last accessed 9 November 2011]
   Google Scholar
• Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009;48:425-32
   PubMed Web of Science ®Google Scholar
• Baraf HSB, Fuentealba C, Greenwald M, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007;34:408-20
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, et al., for the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73
   PubMed Web of Science ®Google Scholar
• Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology 2008;16:53-75
   PubMedGoogle Scholar
• McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001;30:11-18
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006;119:255-66
   PubMed Web of Science ®Google Scholar
• Emery P, Koncz T, Pan S, et al. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clin Ther 2008;30:70-83
   PubMed Web of Science ®Google Scholar
• Dahlberg LE, Holme I, Høye K, et al. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol 2009;38:133-43
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial. Arthritis Rheum 2004;51:549-57
   PubMed Web of Science ®Google Scholar
• Stricker K, Yu S, Krammer G. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. BMC Musculoskelet Disord 2008;9:118
   PubMed Web of Science ®Google Scholar
• Saag K, Van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34
   PubMedGoogle Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87
   PubMed Web of Science ®Google Scholar
• Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-29
   PubMed Web of Science ®Google Scholar
• Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience. Curr Med Res Opin 2006;22:977-88
   PubMed Web of Science ®Google Scholar
• Marenco JL, Pérez M, Navarro FJ, et al. A multicentre, randomised, double-blind study to compare the efficacy and tolerability of dexketoprofen trometamol versus diclofenac in the symptomatic treatment of knee osteoarthritis. Clin Drug Invest 2000;19:247-56
   Web of Science ®Google Scholar
• Liang TH, Hsu PN. Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. Curr Med Res Opin 2003;19:336-41
   PubMed Web of Science ®Google Scholar
• Goregaonkar A, Mathiazhagan KJ, Shah RR, et al. Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with osteoarthritis of the hip or knee: a 4-week, double-blind, randomized, comparative, multicenter study. Curr Ther Res 2009;70:56-68
   PubMed Web of Science ®Google Scholar
• Yocum D, Fleischmann R, Dalgin P, et al., for the Meloxicam Osteoarthritis Investigators. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000;160:2947-54
   Google Scholar
• Valat JP, Accardo S, Reginster J-Y, et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001;50(Suppl 1):S30-4
   PubMedGoogle Scholar
• Chopra A, Bichile L, Rajadhyaksha AG, et al. Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: an Indian experience. APLAR J Rheumatol 2004;7:108-16
   Google Scholar
• Scott DL, Palmer RH. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther 2000;14:443-52
   PubMed Web of Science ®Google Scholar
• Morgan GJ Jr, Kaine J, DeLapp R, et al. Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. J Clin Gastroenterol 2001;32:310-14
   PubMed Web of Science ®Google Scholar
• Huskisson EC, Macciocchi A, Rahlfs VW, et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999;60:253-65
   Web of Science ®Google Scholar
• Omololu B, Alonge TO, Ogunlade SO, et al. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. WAJM 2005;24:128-33
   PubMedGoogle Scholar
• Prabhu VV. A comparative clinical trial evaluating efficacy and safety of fixed dose combination of nimesulide (100 mg) and racemethionine (50 mg) (namsafe) versus reference drug (nimesulide) and other NSAIDs in the treatment of osteo-arthritis. J Indian Med Assoc 2008;106:402-4
   PubMedGoogle Scholar
• Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78
   PubMed Web of Science ®Google Scholar
• Beaulieu AD, Peloso PM, Haraoui B, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manage 2008;13:103-10
   PubMed Web of Science ®Google Scholar
• Zheng W-J, Tang F-L, Li J, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol 2006;9:64-9
   Google Scholar
• Bauer HW, Klasser M, Von Hanstein KL, et al. Oxaceprol is an effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Clin Rheumatol 1999;18:4-9
   PubMed Web of Science ®Google Scholar
• Herrmann G, Steeger D, Klasser M, et al. Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol 2000;19:99-104
   PubMed Web of Science ®Google Scholar
• Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes. A randomised, double-blind study versus diclofenac. Clin Drug Invest 2000;19:15-23
   Web of Science ®Google Scholar
• Singer F, Singer C, Oberleitner H. Phlogenzym versus diclofenac in the treatment of activated osteoarthritis of the knee. A double-blind prospective randomized study. Int J Immunotherapy 2001;17:135-41
   Web of Science ®Google Scholar
• Klein G, Kullich W, Schnitker J, et al. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 2006;24:25-30
   PubMed Web of Science ®Google Scholar
• Akhtar NM, Naseer R, Farooqi AZ, et al. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee – a double-blind prospective randomized study. Clin Rheumatol 2004;23:410-15
   PubMed Web of Science ®Google Scholar
• Jung YB, Seong SC, Lee MC, et al. A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chinese Med 2004;32:291-301
   PubMed Web of Science ®Google Scholar
• Teekachunhatean S, Kunanusorn P, Rojanasthien N, et al. Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. BMC Complement Altern Med 2004;4:19
   PubMedGoogle Scholar
• Medhi B, Kishore K, Singh U, et al. Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytother Res 2009;23:1469-73
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Schubiger BI, Ciccolunghi SN, Tanner K. Once daily dose treatment with a non-steroidal anti-rheumatic drug (diclofenac) in osteoarthrosis. J Int Med Res 1980;8:167-74
   PubMed Web of Science ®Google Scholar
• Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared to diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol 1998;25:1602-11
   Google Scholar
• Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459-64
   PubMed Web of Science ®Google Scholar
• Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716-23
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28
   PubMed Web of Science ®Google Scholar
• Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 2011;27:1359-66
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients. Aliment Pharmacol Ther 2010;32:1240-8
   PubMed Web of Science ®Google Scholar
• Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9
   PubMed Web of Science ®Google Scholar
• Cheung R, Cheng TT, Dong Y, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac:pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis 2010;13:151-7
   PubMed Web of Science ®Google Scholar
• Martinez LL, Oliveira MA, Miguel AS, et al. Enalapril interferes with the effect of diclofenac on leucocyte-endothelium interaction in hypertensive rats. J Cardiovasc Pharmacol 2004;43:258-65
   PubMed Web of Science ®Google Scholar
• Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 2002;42:985-94
   PubMed Web of Science ®Google Scholar
• Lee A, Cooper MG, Craig JC, et al. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database Syst Rev 2007;(2):CD002765
   PubMed Web of Science ®Google Scholar
• Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005;3:489-98
   PubMed Web of Science ®Google Scholar
• Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009;104:356-62
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al.; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81
   PubMed Web of Science ®Google Scholar